Insilico Does the Math, Lilly Writes the Check

Eli Lilly pays $115M upfront to license AI-designed oral drug candidates from Insilico Medicine in a deal worth up to $2.75B

7 Apr 2026

Eli Lilly has placed its largest artificial intelligence wager yet. The company agreed to pay up to $2.75 billion to license preclinical drug candidates from Insilico Medicine, a Hong Kong-based AI drug discovery firm, as it moves to deepen its pipeline in obesity, cancer, and other high-priority therapeutic areas. The deal, announced March 29, 2026, grants Lilly exclusive worldwide rights to develop and commercialize compounds built using Insilico's Pharma.AI platform, which identifies, generates, and optimizes drug molecules faster than conventional laboratory methods allow.

Lilly will pay $115 million at signing. The remaining value is distributed across development, regulatory, and commercial milestones, along with tiered royalties tied to future sales. The agreement also establishes a joint research program, with both companies collaborating on additional discovery efforts across areas Lilly selects. It is the third installment of a deepening relationship: the companies began working together in 2023 through a software licensing arrangement, then expanded with a $100 million research collaboration in late 2025.

Insilico has disclosed more than 40 active programs spanning oncology, metabolic disease, and immunology. Industry reporting suggests at least one GLP-1 obesity candidate is among the assets now transferred to Lilly. Still, the upfront payment may be the deal's most telling detail. At $115 million, it exceeded Insilico's full reported revenues for 2025, reflecting the scale of institutional confidence the transaction represents.

The timing carries strategic weight. The agreement was announced days after the FDA approved Lilly's oral obesity pill, positioning the company to build pipeline depth for the next competitive cycle. Andrew Adams, Lilly's group vice president of molecule discovery, said the collaboration would allow the company to pursue novel mechanisms and identify promising candidates more rapidly than internal research alone could achieve. Yet whether AI-designed compounds will ultimately match the clinical success rates of traditionally discovered drugs remains an open question, one the broader industry will be watching as these partnerships advance through trials.